Amritsar Online

New Webinar Alert – Novel Design Strategies for Effective Next-Generation NLS-Therapeutics

 Breaking News
  • No posts were found

New Webinar Alert – Novel Design Strategies for Effective Next-Generation NLS-Therapeutics

December 14
14:48 2021
Creative Biolabs, as a specialized solution provider in biotechnology, constantly invites elite scientists working in immunology fields to present the latest advancements in their research work as a way of enlightenment. The talk on ADC is scheduled for January 21, 2022.

New York, USA – December 14, 2021 – Creative Biolabs established the ADC sector, providing solutions for researchers studying antibody-drug conjugate, a promising approach of targeted therapy possessing the merits of high specificity as well as affinity towards well-defined targets. Solutions cover one-stop ADC development (e.g., bispecific ADCs, antibody-antibiotic conjugate, antibody-based probe) and high-standard ADC products such as chemical linkers and payloads. Since 2020, Creative Biolabs started holding webinar series involving immunology, and the upcoming event is in January 2022.

“The topic of our next webinar is antibody-drug conjugate,” according to a scientist, “about strategies to improve nuclear localization signal (NLS)-therapeutics.”

Since the main principles guiding nuclear transport were granted the Nobel Prize in 1999, research on the implementation of nuclear localization signal (NLS)-therapeutics has been a hot topic. However, problems still remain in typical NLS-therapeutics that relies on intravenous administration to clear from blood stream and reduce tumor uptake. Creative Biolabs invited Dr. Leyton, an associate professor from the Department of Nuclear Medicine and Radiobiology at Université de Sherbrooke, whose research work delivered a critical breakthrough in escaping endosome entrapment, to present his work on how to investigate NLS-therapeutics nuclear transport dynamics more precisely. In the research of Dr. Leyton, an exclusive ADC molecule functionalized with Accum™ was mentioned.

The webinar will go live on January 21, 2022 at 10 AM (Eastern Time), covering the underlying reason of nuclear targeting improving drug efficacy, mechanism of action of nuclear transport, and challenges of drugs targeting the nucleus.

One notion of Creative Biolabs is continuous learning, which plans to invite several outstanding scientists with great achievements in their specialized areas to present their work every year, as incentives and a reminder that research never stops.

More details about the webinar and Creative Biolabs can be accessed at https://www.creative-biolabs.com/adc.

About Creative Biolabs

Creative Biolabs was established by a group of Ph.D.-level scientists with expertise in biology, chemistry, as well as medical sciences. With over a decade of successful operation, Creative Biolabs has developed into a leading biotech solution provider, with regular clients across the world in pharmaceutical and academic industries. For ADC-related projects, Creative Biolabs can offer a one-stop manner solution, helping clients design, generate, and validate desired ADC molecules.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/adc

Related Articles